Jw Life Science Corp (234080) - Cash Flow Conversion Efficiency

Latest as of March 2026: 0.065x

Based on the latest financial reports, Jw Life Science Corp (234080) has a cash flow conversion efficiency ratio of 0.065x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩14.17 Billion ≈ $9.60 Million USD) by net assets (₩218.75 Billion ≈ $148.24 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Jw Life Science Corp for the company's overall valuation and market capitalisation.

Jw Life Science Corp - Cash Flow Conversion Efficiency Trend (2015–2025)

This chart illustrates how Jw Life Science Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Jw Life Science Corp Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Jw Life Science Corp ranked by their cash flow conversion efficiency. Explore Jw Life Science Corp earnings quality ratio to measure how well operating cash flow supports reported net income.

Company	Cash Flow Conversion Efficiency
Rupa & Company Limited NSE:RUPA	0.023x
Hitejinro Holdings KO:000140	-0.020x
EKOS IS:EKOS	0.009x
China Electric Manufacturing Corp TW:1611	0.009x
Goltas Goller Bolgesi Cimento Sanayi ve Ticaret AS IS:GOLTS	0.042x
Cellectis PA:ALCLS	-0.255x
Complete Solaria, Inc. Common Stock NASDAQ:CSLR	1.474x
Novem Group S.A. XETRA:NVM	0.229x

Annual Cash Flow Conversion Efficiency for Jw Life Science Corp (2015–2025)

The table below shows the annual cash flow conversion efficiency of Jw Life Science Corp from 2015 to 2025. View current stock price of Jw Life Science Corp for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	₩220.58 Billion ≈ $149.48 Million	₩40.54 Billion ≈ $27.47 Million	0.184x	-27.33%
2024-12-31	₩200.44 Billion ≈ $135.84 Million	₩50.69 Billion ≈ $34.35 Million	0.253x	+7.28%
2023-12-31	₩159.39 Billion ≈ $108.02 Million	₩37.57 Billion ≈ $25.46 Million	0.236x	+134.14%
2022-12-31	₩140.33 Billion ≈ $95.10 Million	₩14.13 Billion ≈ $9.57 Million	0.101x	-56.11%
2021-12-31	₩131.49 Billion ≈ $89.11 Million	₩30.17 Billion ≈ $20.44 Million	0.229x	-35.20%
2020-12-31	₩132.06 Billion ≈ $89.50 Million	₩46.75 Billion ≈ $31.68 Million	0.354x	+78.82%
2019-12-31	₩122.62 Billion ≈ $83.09 Million	₩24.28 Billion ≈ $16.45 Million	0.198x	-40.13%
2018-12-31	₩109.26 Billion ≈ $74.04 Million	₩36.13 Billion ≈ $24.48 Million	0.331x	+53.12%
2017-12-31	₩102.10 Billion ≈ $69.19 Million	₩22.05 Billion ≈ $14.94 Million	0.216x	+21.27%
2016-12-31	₩90.30 Billion ≈ $61.20 Million	₩16.08 Billion ≈ $10.90 Million	0.178x	-43.04%
2015-12-31	₩82.83 Billion ≈ $56.13 Million	₩25.90 Billion ≈ $17.55 Million	0.313x	--

About Jw Life Science Corp

KO:234080 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$114.80 Million

₩169.40 Billion KRW

Market Cap Rank

#18745 Global

#869 in Korea

Share Price

₩10940.00

Change (1 day)

-0.55%

52-Week Range

₩10720.00 - ₩15500.00

All Time High

₩26817.34